Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | US

Overview

Corporate Details

ISIN(s):: US2528281080 (+1 more)
LEI:
Country:: United States of America
Address:: 7 TIMES SQUARE, 10036 NEW YORK
Website:: https://dianthustx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
KWANGDONG PHARMACEUTICAL CO.,LTD Developing drugs & health goods by integrating oriental and Western medicine.	South Korea	009290
Kyivmedpreparat A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.	Ukraine	KMED
KYONGBO PHARMACEUTICAL CO., LTD. Manufactures APIs and finished drugs, offering global CDMO services from development to production.	South Korea	214390
KYORIN Pharmaceutical Co., Ltd. Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.	Japan	4569
Kyowa Kirin Co.,Ltd. Develops antibody medicines for oncology, nephrology, immunology, and allergy.	Japan	4151
KyungdongPharm Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.	South Korea	011040
KYUNG NAM PHARM.CO.,LTD. South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.	South Korea	053950
Kyverna Therapeutics, Inc. Developing CAR T-cell therapies for durable remission in autoimmune diseases.	United States of America	KYTX
Labiana S.A. Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.	Spain	LAB
Labocanna Spolka Akcyjna Cultivates and distributes medical marijuana and cannabinoid products for clinical and consumer use.	Poland	LCN